RTTR - Ritter Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development13,292.4882,260.297113.931
Selling General and Administrative5,154.2396,648.1062,167.691
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-18,446.727-8,908.403-2,281.622
Income from Continuing Operations
Total Other Income/Expenses Net62.093120.63221.673
Earnings Before Interest and Taxes-18,384.634-8,787.771-2,259.949
Interest Expense--213.516
Income Before Tax-18,384.634-8,787.771-2,473.465
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-18,384.634-8,787.771-2,473.465
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-18,384.634-8,787.771-2,473.465
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-18,384.634-9,178.623-3,071.507